New epigenetic study reveals exciting insights into colorectal cancer progression

September 11, 2015, Nanjing University School of Life Sciences
Cancer — Histopathologic image of colonic carcinoid. Credit: Wikipedia/CC BY-SA 3.0

Researchers at Nanjing University, China, found new epigenetic markers for colorectal cancer which may offer a new approach for treatment.

Epigenetic alterations leading to colorectal carcinogenesis are thought to hold great promise for the development of novel, minimally invasive molecular biomarkers.

Scientists at the State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, China, have demonstrated that heterochromatin protein HP1γ was critical for CRC cell proliferation and could be specially regulated by miR-30a at the protein level.

"These studies have improved the chances that epigenetic biomarkers will find a place in the clinical practices of screening, early diagnosis, prognosis, therapeutic choice and recurrence surveillance for CRC patients." says Professor Quan Zhao, who is one of the principal investigators at School of Life Sciences, Nanjing University, China.

In the future Professor Zhao and his collaborators want to further investigate the role of these new markers in individual steps of invasion-metastasis cascade of CRC.

Key findings included:

  • HP1γ protein levels were significantly increased in primary CRC tissues compare to adjacent non-tumor tissues. Cancer correlation analysis indicated prognostic potential. Thus, HP1γ appears to be a promising biomarker for CRC and may provide an effective target for CRC therapy.
  • MiR-30a was down-regulated in CRC tissues, and exhibited a significant inverse correlation with the HP1γ . Further, HP1γ could be post-transcriptionally regulated by miR-30, which suppressed growth both in vitro and in vivo, suggesting that miR-30a can serve as another potential prognostic biomarker for CRC, may also have promise as therapeutics.

Their study results are published in the OnlineFirst issue of Cancer Research (September 2, 2015; DOI: 10.1158/0008-5472). Liu et al.: Heterochromatin HP1γ promotes colorectal progression and is regulated by miR-30a

Explore further: Serum miR-21 putative biomarker for colorectal cancer

Related Stories

Serum miR-21 putative biomarker for colorectal cancer

June 20, 2013
(HealthDay)—The oncogenic microRNA (miRNA) miR-21 is a potential biomarker for detection and prognosis of colorectal cancer (CRC), according to a study published in the June 19 issue of the Journal of the National Cancer ...

Study identifies a likely key driver of colorectal cancer development and progression

April 14, 2014
A new study identifies a molecule that is a probable driving force in colorectal cancer and suggests that the molecule could be an important target for colorectal cancer treatment and a valuable biomarker of tumor progression.

Reducing resistance to chemotherapy in colorectal cancer by inhibition of PHD1

August 19, 2015
Scientists at VIB and KU Leuven have shown that blocking the PHD1 oxygen sensor hinders the activation of p53, a transcription factor that aids colorectal cancer (CRC) cells in repairing themselves and thus resisting chemotherapy. ...

Promising blood biomarkers identified for colorectal cancer: Is a screening blood test within reach?

October 22, 2014
The search for blood-borne biomarkers that could be used to screen for colorectal cancer (CRC) has uncovered two promising candidates that may one day lead to the development of a simple blood test. Scientists have been piecing ...

Study shows colorectal cancer genetically different in older and younger patients

May 29, 2015
While the overall rate of colorectal cancer (CRC) is declining, CRC specifically among young patients is increasing. Previous studies have shown that CRC in patients younger than 50 years old tends to be more aggressive than ...

Poor survival among colorectal cancer patients tied to biomarker CSN6

August 10, 2015
A protein called CSN6 has been found to be correlated with poor survival among patients with colorectal cancer, according to a study at The University of Texas MD Anderson Cancer Center.

Recommended for you

Fully reprogrammed virus offers new hope as cancer treatment

May 25, 2018
A cancer treatment that can completely destroy cancer cells without affecting healthy cells could soon be a possibility, thanks to research led by Cardiff University.

Research could help fine-tune cancer treatment

May 25, 2018
Cancer therapies that cut off blood supply to a tumour could be more effective in combination with existing chemotherapeutic drugs—according to new research from the University of East Anglia.

Increasing physical activity linked to better immunity in breast cancer patients, study finds

May 25, 2018
A new study from the University of Toronto's Faculty of Kinesiology & Physical Education has found that moderate to vigorous physical activity may help regulate the levels of C-reactive protein – an important biomarker ...

Low-fat diet tied to better breast cancer survival

May 24, 2018
(HealthDay)—Breast cancer patients who adopted a low-fat diet were more likely to survive for at least a decade after diagnosis, compared to patients who ate fattier fare, new research shows.

A cascade of immune processes offers insights to triple-negative breast cancer

May 24, 2018
Cancer is crafty. To survive and thrive, tumors find a way of thwarting our body's natural systems.

By forming clots in tumors, immune cell aids lung cancer's spread

May 24, 2018
University of North Carolina Lineberger Comprehensive Cancer Center researchers have found that by helping to form clots within tumors, immune cells that flock to a particular type of lung cancer are actually building a foundation ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.